Back HIV/AIDS

HIV / AIDS

AIDS 2016: Bone Loss Recovers After Stopping PrEP, Biannual Kidney Monitoring Enough for Most

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilized after a year and those who stopped taking it began to see a reversal of the decline, researchers reported last week at the 21st International AIDS Conference (AIDS 2016) in Durban. Another study found that clinically relevant declines in kidney function among Truvada PrEP users are rare and monitoring every 6 months is adequate for most people.

alt

AIDS 2016: Study Looks at Comprehensive HIV Treatment and Prevention Services for Sex Workers

A randomized trial of female sex workers in Zimbabwe, offering enhanced access to HIV treatment and pre-exposure prophylaxis (PrEP), has failed to show that the extra services helped reduce the proportion with detectable viral load, Frances Cowan reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban. However, it appears that the comprehensive set of sex worker-friendly services offered in the control arm may have already been enough to substantially improve the health of participants.

alt

AIDS 2016: Dolutegravir Plus Lamivudine Works Well as First-Line HIV Treatment

A 2-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a small pilot study, according to a late-breaker presentation at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

AIDS 2016: Large Test-and-Treat Study Fails to Show Impact on New HIV Infections

The first major research study of "test and treat" as a public health intervention to report its final results -- ANRS 12249 -- has found that the strategy failed to reduce new HIV infections in the African communities where it was provided, according to a report at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

AIDS 2016: More Confidence on Zero Risk -- Still No Linked HIV Infections in PARTNER Study

The PARTNER study, which 2 years ago generated headlines by establishing that the chance of an HIV-positive person with an undetectable viral load transmitting the virus was very low and quite possibly zero, released new data last week at the 21st International AIDS Conference (AIDS 2016) that further refined this estimate. The findings were also published in the July 12 New England Journal of Medicine.

alt

AIDS 2016: Progress Towards 90-90-90 Targets in Southern Africa -- Find the Men!

Studies of treatment cascade performance in South Africa and Namibia show large variations between districts and highlight the need for up-to-date information on performance to guide programming, advocacy, and funding, according to presentations at the 21st International AIDS Conference (AIDS 2016) last week in Durban. In particular, the studies emphasized the low rates of HIV diagnosis among men in the region, and low rates of viral suppression, especially among men.

alt

AIDS 2016: New HIV Vaccine Efficacy Trial Set to Start this Year

A new efficacy trial for an HIV vaccine -- only the seventh ever conducted in the history of the epidemic -- will start this November, delegates heard at the 21st International AIDS Conference (AIDS 2016) taking place this week in Durban. The HVTN 702 study will enroll 5400 men and women in southern Africa, and is planned to last for 4 years. In May it was announced that a pilot study, HVTN 100, had met the criteria for the vaccine being taken forward into the larger study. But this week was the first time researchers revealed how well it had met those criteria.

alt